Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Clin Infect Dis · 2017 · PMC5848255 · PMID 30060024

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Participants treated with bezlotoxumab also had fewer all-cause readmissions (absolute difference, −3.7%; 95% CI, −9.0 to 1.5; relative difference, −12.1%) than inpatients randomized to placebo ( Figure 1A ), although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.